Spero Therapeutics, Inc. (SPRO): Price and Financial Metrics
SPRO Price/Volume Stats
Current price | $1.72 | 52-week high | $2.00 |
Prev. close | $1.75 | 52-week low | $0.99 |
Day low | $1.72 | Volume | 154,000 |
Day high | $1.76 | Avg. volume | 313,503 |
50-day MA | $1.59 | Dividend yield | N/A |
200-day MA | $1.39 | Market Cap | 92.65M |
SPRO Stock Price Chart Interactive Chart >
SPRO POWR Grades
- Value is the dimension where SPRO ranks best; there it ranks ahead of 99.28% of US stocks.
- SPRO's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
- SPRO's current lowest rank is in the Momentum metric (where it is better than 10.87% of US stocks).
SPRO Stock Summary
- Price to trailing twelve month operating cash flow for SPRO is currently 2.69, higher than only 7.96% of US stocks with positive operating cash flow.
- The ratio of debt to operating expenses for SPERO THERAPEUTICS INC is higher than it is for about just 12.29% of US stocks.
- Revenue growth over the past 12 months for SPERO THERAPEUTICS INC comes in at 781.74%, a number that bests 98.98% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to SPERO THERAPEUTICS INC are SPCE, ADAP, GWH, GBIO, and CBAY.
- SPRO's SEC filings can be seen here. And to visit SPERO THERAPEUTICS INC's official web site, go to sperotherapeutics.com.
SPRO Valuation Summary
- SPRO's price/sales ratio is 1; this is 54.55% lower than that of the median Healthcare stock.
- Over the past 75 months, SPRO's EV/EBIT ratio has gone down 13.3.
Below are key valuation metrics over time for SPRO.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
SPRO | 2023-12-29 | 1.0 | 1.5 | -48.3 | -16.9 |
SPRO | 2023-12-28 | 1.0 | 1.4 | -48.0 | -17.8 |
SPRO | 2023-12-27 | 1.0 | 1.4 | -46.0 | -23.1 |
SPRO | 2023-12-26 | 1.0 | 1.4 | -47.6 | -18.8 |
SPRO | 2023-12-22 | 0.9 | 1.3 | -44.3 | -27.6 |
SPRO | 2023-12-21 | 0.9 | 1.3 | -44.7 | -26.6 |
SPRO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SPRO has a Quality Grade of C, ranking ahead of 28.84% of graded US stocks.
- SPRO's asset turnover comes in at 0.128 -- ranking 241st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows SPRO's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.128 | 1 | -1.651 |
2021-03-31 | 0.108 | 1 | -1.872 |
2020-12-31 | 0.072 | 1 | -2.390 |
2020-09-30 | 0.094 | 1 | -2.720 |
2020-06-30 | 0.110 | 1 | -2.104 |
2020-03-31 | 0.108 | 1 | -1.684 |
SPRO Price Target
For more insight on analysts targets of SPRO, see our SPRO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $38.17 | Average Broker Recommendation | 1.58 (Moderate Buy) |
Spero Therapeutics, Inc. (SPRO) Company Bio
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is based in Cambridge, Massachusetts.
Latest SPRO News From Around the Web
Below are the latest news stories about SPERO THERAPEUTICS INC that investors may wish to consider to help them evaluate SPRO as an investment opportunity.
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call TranscriptSpero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call Transcript November 13, 2023 Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.04, expectations were $-0.15. Ted Jenkins: Thank you, operator, and thank you all for participating in today’s conference call. This afternoon, Spero Therapeutics released financial results and provided a pipeline update for the third […] |
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business UpdateSpecial Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr; Trial expected to begin with First Patient, First Visit in 4Q 2023 Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR |
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 13, 2023 at 4:30 p.m. ET to report its third quarter 2023 financial results and provide |
Spero Therapeutics to Present at Upcoming November Investor ConferencesCAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer, will be available for one-on-one meetings at the Truist Securities BioPharma Symposium, to be held at |
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business OfficerMs. Rajavelu brings over two decades of experience in the life sciences sector focused on strategic growth, financing, M&A, and investor relations.CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced the appointment of |
SPRO Price Returns
1-mo | 3.61% |
3-mo | 17.01% |
6-mo | 42.15% |
1-year | 19.44% |
3-year | -87.37% |
5-year | -86.57% |
YTD | 17.01% |
2023 | -15.03% |
2022 | -89.19% |
2021 | -17.43% |
2020 | 101.66% |
2019 | 56.34% |
Continue Researching SPRO
Want to do more research on Spero Therapeutics Inc's stock and its price? Try the links below:Spero Therapeutics Inc (SPRO) Stock Price | Nasdaq
Spero Therapeutics Inc (SPRO) Stock Quote, History and News - Yahoo Finance
Spero Therapeutics Inc (SPRO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...